Supplementary Materials for:

YAP Activity Is Not Associated with Survival of Uveal Melanoma Patients and Cell Lines

Yong Joon Kim¹, Sung Chul Lee¹, Sung Eun Kim¹, Seo Hee Kim¹, Sang Kyum Kim²*, Christopher Seungkyu Lee¹*

¹Department of Ophthalmology, The Institute of Vision Research, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

²Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

*Co-corresponding authors

Supplementary Materials

Supplementary Figure 1. Heat map of genes with core enrichment using Gene Set Enrichment Analysis in high and low YAP signature groups.

Supplementary Figure 2. Correlation between YAP activity and tumor size.

Supplementary Figure 3. qRT-PCR analyses of YAP mRNA expression level after the treatment of control siRNA and YAP/TAZ siRNA for 48 h.

Supplementary Figure 4. Effects of siRNA-mediated YAP knockdown on cellular proliferation in multiple uveal melanoma cell lines (92.1, MP41, MP46, and MP65) and other cell lines.

Supplementary Table 1. List of metastatic sites in the YAP nuclear positive and negative groups.

Supplementary Table 2. List of genes used for the YAP signature analysis (from MsigDB)
Supplementary Figure 1. Heat map of genes with core enrichment using Gene Set Enrichment Analysis in high and low YAP signature groups. Gene expression level of two representative YAP target gene, CTGF and CYR61 in high and low YAP signature groups, are also shown. Error bars represent SEM.
Supplementary Figure 2. Correlation between YAP activity and tumor size. (a and b) YAP mRNA expression levels and tumor sizes. (c and d) The Gene Set Variant Enrichment scores for YAP signature and tumor size.
Supplementary Figure 3. qRT-PCR analyses of YAP mRNA expression level after the treatment of control siRNA and YAP/TAZ siRNA for 48 h. Error bars represent SEM (n = 3 independent experiments)
Supplementary Figure 4. Effects of siRNA-mediated YAP knockdown on cellular proliferation in multiple uveal melanoma cell lines (92.1, MP41, MP46, and MP65) and other cell lines. Viable cells were quantified at 72 hours after siRNA transfection. Error bars represent standard error of the mean (n = 3 independent experiments).
**Supplementary Table 1.** List of metastatic sites in the YAP nuclear negative and positive groups.

| No. | Age (y) | Sex | Metastasis site                      | No. | Age (y) | Sex | Metastasis site                      |
|-----|---------|-----|--------------------------------------|-----|---------|-----|--------------------------------------|
| 1   | 66      | F   | Liver                                | 20  | 30      | F   | Liver, Lung                          |
| 2   | 66      | M   | Liver                                | 21  | 43      | F   | Liver                                |
| 3   | 31      | F   | Lung                                 | 22  | 48      | M   | Liver                                |
| 4   | 61      | M   | Liver, Lung, Pleura, Bone            | 23  | 33      | M   | Liver                                |
| 5   | 54      | F   | Liver                                | 24  | 45      | F   | Liver                                |
| 6   | 48      | F   | Liver, Lung, Abdominal wall          | 25  | 25      | F   | Liver                                |
| 7   | 55      | F   | Bladder                              | 26  | 54      | F   | Liver, Kidney                        |
| 8   | 42      | F   | Liver                                | 27  | 70      | F   | Liver                                |
| 9   | 45      | M   | Liver                                | 28  | 52      | F   | Liver, Lung, Bone, LN                |
| 10  | 63      | M   | Liver                                | 29  | 57      | M   | Liver                                |
| 11  | 49      | M   | Liver, Adrenal gland                 | 30  | 78      | M   | Liver, Bone                          |
| 12  | 26      | M   | Liver                                | 31  | 19      | M   | Liver, Bone                          |
| 13  | 55      | F   | Liver, Spleen, Spine                 | 32  | 52      | F   | Liver, Lung, Pancreas, Bone, Abdominal wall |
| 14  | 51      | M   | Liver, Bone                          | 33  | 58      | M   | Brain, Bone, Stomach                 |
| 15  | 37      | F   | Liver, Bone                          | 34  | 73      | M   | Liver                                |
| 16  | 49      | M   | Liver, Lung, Bone                    | 35  | 55      | M   | Liver, Lung, Bone                    |
| 17  | 50      | M   | Liver                                | 36  | 57      | F   | Liver, Bone                          |
| 18  | 67      | M   | Liver                                | 37  | 51      | M   | Liver, Kidney, LN                    |
| 19  | 57      | M   | Liver                                | 38  | 46      | M   | Liver                                |

Y = years, M = male, F = female
**Supplementary Table 2.** List of genes used for the YAP signature analysis (from MsigDB).

| NCBI (Entrez) Gene ID | Gene symbol | NCBI (Entrez) Gene ID | Gene symbol |
|-----------------------|-------------|-----------------------|-------------|
| 10397                 | NDRG1       | 2013                  | EMP2        |
| 3925                  | STMN1       | 27063                 | ANKRD1      |
| 10099                 | TSPAN3      | 3161                  | HMMR        |
| 7052                  | TGM2        | 11167                 | FSTL1       |
| 1843                  | DUSP1       | 1854                  | DUT         |
| 7057                  | THBS1       | 23576                 | DDAH1       |
| 3693                  | ITGB5       | 1490                  | CTGF(= CCN2) |
| 1601                  | DAB2        | 1063                  | CENPF       |
| 3491                  | CYR61 (= CCN1) | 4616              | GADD45B     |
| 7153                  | TOP2A       | 9353                  | SLIT2       |
| 26227                 | PHGDH       | 7042                  | TGFB2       |
| 6624                  | FSCN1       | 5376                  | PMP22       |
| 4082                  | MARCKS      | 10395                 | DLC1        |
| 6446                  | SGK1        | 2744                  | GLS         |
| 3074                  | HEXB        | 80114                 | BICC1       |
| 332                   | BIRC5       | 2316                  | FLNA        |
| 2621                  | GAS6        | 7139                  | TNNT2       |
| 7083                  | TK1         | 1285                  | COL4A3      |
| 51232                 | CRIM1       | 29969                 | MDFIC       |
| 5054                  | SERPINE1    | 10186                 | LHFPL6      |
| 558                   | AXL         | 8436                  | CAVIN2      |
| 3689                  | ITGB2       | 7145                  | TNS1        |
| 991                   | CDC20       | 64236                 | PDLIM2      |
| 51421                 | AMOTL2      | 79801                 | SHCBP1      |
| 2119                  | ETV5        | 63898                 | SH2D4A      |
| 8836                  | GGH         | 1894                  | ECT2        |
| 29970                 | SCHIP1      | 50807                 | ASAP1       |
| 1031                  | CDKN2C      | 3268                  | AGFG2       |
| 2247                  | FGF2        |                       |             |